Setmelanotide
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity
Rhythm · Phase 2 · Completed · Enrollment 213
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| 16p11.2 Cohort | n/r | n/r | n/r | n/r |
| AS Cohort | n/r | n/r | n/r | n/r |
| BBS Cohort | n/r | n/r | n/r | n/r |
| MC4R Cohort | n/r | n/r | n/r | n/r |
| POMC/PCSK1/LEPR Heterozygous Cohort | n/r | n/r | n/r | n/r |
| POMC/PCSK1/LEPR Composite Heterozygous Cohort | n/r | n/r | n/r | n/r |
| POMC/PCSK1/LEPR Compound Heterozygous Cohort | n/r | n/r | n/r | n/r |
| SH2B1 Cohort | n/r | n/r | n/r | n/r |
| SMS Cohort | n/r | n/r | n/r | n/r |
| SRC1 Cohort | n/r | n/r | n/r | n/r |
Not shown
- 16p11.2 Cohort: endpoint not reported
- AS Cohort: endpoint not reported
- BBS Cohort: endpoint not reported
- MC4R Cohort: endpoint not reported
- POMC/PCSK1/LEPR Heterozygous Cohort: endpoint not reported
- POMC/PCSK1/LEPR Composite Heterozygous Cohort: endpoint not reported
- POMC/PCSK1/LEPR Compound Heterozygous Cohort: endpoint not reported
- SH2B1 Cohort: endpoint not reported
- SMS Cohort: endpoint not reported
- SRC1 Cohort: endpoint not reported